Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials.

Andrews, J Scott; Desai, Urvi; Kirson, Noam Y; Zichlin, Miriam L; Ball, Daniel E; Matthews, Brandy R

Andrews, J Scott; Desai, Urvi; Kirson, Noam Y; Zichlin, Miriam L; Ball, Daniel E; Matthews, Brandy R.

Afiliación

Andrews JS; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Desai U; Analysis Group, Inc., Boston, MA, USA.
Kirson NY; Analysis Group, Inc., Boston, MA, USA.
Zichlin ML; Analysis Group, Inc., Boston, MA, USA.
Ball DE; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Matthews BR; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.

Alzheimers Dement (N Y) ; 5: 354-363, 2019.

Article en En | MEDLINE | ID: mdl-31417957

Palabras clave

Alzheimer's disease; CDR; FAQ; MCID; MMSE; Meaningful decline

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Alzheimers Dement (N Y) Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google